Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
about
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.Recent therapeutic advances in chronic lymphocytic leukemia.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Discovery and application of immune biomarkers for hematological malignancies.Treatment of Richter's Syndrome.Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.Cardiotoxicity of immune checkpoint inhibitors.Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in CancerExpression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphomaBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitorsAnti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysisCheckpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
P2860
Q38646074-A4A1590F-878D-4EE9-8D6B-8EA100AE6FBCQ42352191-6C59496F-086F-4200-801F-4B3035767A13Q46318389-2E3E7E4E-DB0A-4BD6-87AE-2C7E4C35FFAAQ47120629-D57B8120-6244-439A-A059-13F0A9D6CA5FQ47329066-6E1E2B40-0C10-4C90-B2A9-E886CBA59A9DQ47424027-DE8F3934-BE5D-4E78-B399-CB248CFD8DC9Q47681393-D1A02E9A-FC84-4CE3-998E-4ED09DE174CCQ49843910-4D36C887-0EBA-47BA-942F-3C1DE9A2F12FQ50074012-0188B7EE-C645-444F-B117-1FD512DC69B8Q50110556-D43C1FC8-400C-454D-8E15-E50207F134F1Q51804722-E8A86CB1-7877-4DF2-89FC-FBDFF7889632Q52721221-361A3255-B43A-464A-9CCA-12AC14817AB5Q54979456-B0040787-410D-4651-A62C-A5648CD47F48Q55438414-C6239F46-8B50-4F84-8792-EF3985EC0B96Q56891212-3190DCEA-41AD-42DF-B75E-732785E70FB6Q58691451-BCA448C2-40CA-4248-A62F-5A7514F7A9E5Q58713932-87D556B3-AD91-40C4-BD02-BA99B2073196Q59132267-520EB8F5-438F-485E-967E-7131CC413B58Q59135661-9C9CAE03-737E-4839-B2B8-CE85186760D7
P2860
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@en
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@nl
type
label
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@en
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@nl
prefLabel
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@en
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@nl
P2093
P2860
P1433
P1476
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
@en
P2093
Andrew L Feldman
Asher A Chanan-Khan
Betsy R LaPlant
Casey N Aitken
Charla R Secreto
Daniel L Van Dyke
David S Viswanatha
Deborah A Bowen
Erik Asmus
Esteban Braggio
P2860
P304
P356
10.1182/BLOOD-2017-02-765685
P407
P577
2017-04-19T00:00:00Z